CoChat

Is Depression the Wrong Treatment Target for Improving Outcome in Coronary Artery Disease?

Open access
Rafanelli, Chiara, Sirri, Laura, Grandi, Silvana, Fava, Giovanni A. · 2013 · Psychotherapy and Psychosomatics
Cited by 34

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

A significant relationship between depression and cardiac morbidity has been documented [1]. The identification of depression as an unfavorable marker of the clinical course in coronary artery disease (CAD) in the 1990s [2,3,4] generated the hope of improving the prognosis of cardiovascular disease with treatment of depression. This hope, however, has not survived the test of time. In a Cochrane review on randomized controlled clinical trials (RCTs) of any length of treatment and any length of follow-up [5], psychological and pharmacological interventions have shown a small yet clinically meaningful effect on depression outcomes in CAD patients. However, no beneficial effects on the reduction of mortality rates and cardiac events have been found. Indeed, in some cases, treatment of depression was found to entail negative physical consequences. There are several potential explanations, involving drugs and psychotherapy, which account for this phenomenon.The evidence that is available in psychiatric settings suggests that the positive effects of antidepressant drugs are related to symptom severity [6]. Indeed, the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) [7], on depressed patients after CAD, found that the effect of sertraline was greater in patients with severe and recurrent depression. It is also true that, in cardiac settings, mild depressive symptoms are sufficient to enhance cardiovascular risk even in the absence of major depressive disorder [8,9,10,11]. Antidepressant treatment could thus be successful in terms of cardiac prognosis only in the subgroup of cardiac patients with more severe depression, but not in those with milder depression at equally elevated cardiac risk.It has been suggested that selective serotonin reuptake inhibitors (SSRIs) might ameliorate the adverse effect of depression on cardiovascular disease through the inhibition of platelet aggregation, even independently of changes in depression [12]. This potential benefit, however, is counteracted by recognized adverse cardiovascular side effects [13,14,15]. In particular, the use of SSRIs such as citalopram and escitalopram is associated with cases of arrhythmias and prolonged QTc interval on electrocardiogram in patients lacking cardiovascular disorders [16]. Licht et al. [17] found that all antidepressants, including SSRIs, have a lowering effect on cardiac vagal control that has been found to be associated with increased blood pressure and other metabolic abnormalities, such as unfavorable lipid profiles and high glucose levels [18].It is also well recognized that the potential for drug-drug interactions increases with the number of medication used [19] and this is a common problem for cardiac patients. Labos et al. [20] found that the use of an SSRI combined with dual antiplatelet therapy (including clopidogrel and ASA) was associated with an increased risk of gastrointestinal bleeding, hemorrhagic stroke or other bleeding that either necessitated admission to hospital or occurred in hospital during follow-up, compared with ASA use alone. Again, such drug-drug interactions may counteract the potential benefits of SSRIs on platelet aggregation.The modest effects of antidepressant drugs in improving depression and the lack of effects on cardiovascular prognosis may also depend on the loss of clinical effects refractory to dosage increase, with enhanced susceptibility to subsequent episodes of depression, observed after long-term use of antidepressant drugs [21]. In patients with bipolar illness, these phenomena may involve switching into mania/hypomania and/or episode acceleration [21] and account for the failure of antidepressant drugs to improve long-term cardiovascular outcome.On the whole, standardized approaches for the treatment of depression by psychotherapy have also failed to provide benefit to cardiac patients in clinical trials. The ENRICHD study [22] found significant improvements in patients' levels of depression and social support 6 months after initiation of cognitive-behavior therapy (CBT) compared with care as usual, even though differences between the arms diminished over time and were no longer present at 30 months. It is likely that the approach failed to affect cardiac prognosis due to the short-term nature of the effects.In the same vein, the CREATE study [23] found no advantage in reducing depression with a dozen 50-min sessions of interpersonal psychotherapy (IPT) compared with weekly 20-min clinical management sessions with clinicians who encouraged adherence and gave information about depression, discussed medication use and provided reassurance [24]. The results of this trial suggested the possibility of the unfavorable effects of psychological treatment on both depression and the cardiocirculatory system. In fact, patients randomized to IPT reported fatigue more frequently than those assigned to clinical management. They also experienced a slight increase in systolic blood pressur

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000351586

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

Metadata

Authors
Rafanelli, C., Sirri, L., Grandi, S., & Fava, G. A.
Venue
Psychotherapy and Psychosomatics
Publisher
S. Karger AG
Published
2013
Volume
82
Issue
5
Pages
285-291
ISSN
  • 0033-3190 (ISSN-L)
  • 1423-0348
OpenAlex
W2088289406
Cited by
34
References
27
FWCI
3.18
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.